The shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN) fell as much as 17.68% after its announcement about the denial of its FDA rescission of the ANCHOR clinical trial Special Protocol Assessment (SPA) agreement. The Office of New Drugs (OND) working under the Food and Drug Administration Department (FDA) denied Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s appeal.…